URINE SPECIMEN IN DETECTION OF HEPATITIS A VIRUS ANTIBODY IN CHILDREN
Downloads
Hepatitis A is still a problem in developing country, especially in Indonesia. Twenty-three thousand cases per year in the world were reported by CDC in 1998. Detection of Hepatitis A Virus (HAV) antibody needs blood specimen, for which the drawing procedure is quite unpleasant for children. The purpose of present study is to examined the use of urine as an alternative specimen compared to blood in the detection of HAV antibody. A cross sectional study on children age 5–12 years who lived in Rusun Sombo District Simokerto Surabaya was performed in 2007. Blood and urine specimens were taken from all subjects, further tested with Microparticle Enzyme Immunoassay (MEIA) method using AxSym®
HAVAB® 2.0. A total 74 children were included in the study, 43 (58.1%) were boys. Seropositive was found in 38 (51.4%) children and uropositive in 3 (4%) children. There are significant differences between blood and urine specimen, with sensitivity 7.9%, spesificity 100%, PPV 100% and NPV 50.7%. Urine could not replace blood specimen as the gold standart for the detection of hepatitis A antibody in children
2. Sulaiman AH, Julitasari. Hepatitis A. In: Sulaiman AH, Julitasari,
editors. Virus Hepatitis A sampai E di Indonesia. 1st ed. Jakarta: Musady, 1995. p. 1–15.
3. Joshi MS, Chitambar SD, Arankalle VA, et al. Evaluation of Urine
as a Clinical specimen for Diagnosis of Hepatitis A. Clin Diag Lab Immunol 2002; 10: 840–5.
4. Rodriguez LA, Diaz OL, Casanueva RM, et al. Anti-Hepatitis A Virus Immunoglobulin M Antibodies in Urine Samples for Rapid Diagnosis of Outbreaks. Clin J Diag Lab Immunol 2003; 10: 492–4.
5. Lee C, Ghadessi M, Lei JD, Hall G, Sustarsic D, El Shami AS.
Detection of Total Antibodies to Hepatitis A Virus (HAV) by IMMULITE® and IMMULITE® 2000. 2003. DPC Scientific
Poster.
6. Tomasi TB, Larson L, Challacombe S, McNabb P. Mucosal immunity: The origin and migration patterns of cells in the secretory system. Postgraduate course presentation 1980; 1(65): 12–9.
7. Roitt I. Antibodies. In: Roitt I, Brostoff J, Male D, editors. 6
ed. Mosby, 2001. p. 65–85.
8. Spiekermann GM, Finn PW, Ward ES, Durmont J, Dickinson BL,
Blumberg RS, et al. Receptor-mediated immunoglobulin G transport
across mucosal barriers in adult life: functional expression of FcRn
in the mammalian lung. J Exp Med 2002; 303–10.
9. Mayer L. Mucosal Immunity. Pediatrics 2003; 111(6): 1595–600.
10. Woof JM, Mestecky J. Mucosal Immunoglobulins. Immunological
reviews 2005; 206: 64–82.
11. Lemon SM, Binn LN. Serum Neutralizing Antibody Response to
Hepatitis A Virus. J Infect Dis 1983; 148(6): 1033–9.
12. Cole M, Perry K. Hepatitis A Serological Assay: A Review of
Evaluation Literature. http://www.pasa.nhs.uk/cep (Accessed at
March, 2006)
13. Sherlock S, Dooley J. Virus Hepatitis. In: Sherlock S, Dooley J,
editors. Diseases of the Liver and Biliary System. 9
th ed. London: Blackwell Scientific Publications 1993. p. 266–9.
14. Bisanto J. Permasalahan Penyakit Hepatitis Virus di Indonesia. In: Zulkarnain Z, Bisanto J, Pujiarto PS, Oswari H, editors. Tinjauan
Komprehensif Hepatitis Virus pada Anak. 1
st ed. Jakarta: Balai Penerbit FK-UI 2000. p. 9–31.
15. El-Kamary SS. In Brief: Hepatitis A. Peds In Rev 2003; 26(2): 75–6.
16. Lemon SM. Type A Viral Hepatitis: epidemiology, diagnosis and
prevention. Clin Chem 1997; 43: 1494–9.th
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
